^
    Back
    Association details:
    Biomarker:BRAF V600E
    Cancer:Glioblastoma
    Drug:Mektovi (binimetinib) (MEK inhibitor) +
    Braftovi (encorafenib) (BRAF inhibitor, cRAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Melanoma)
    New
    Excerpt:
    BRAFTOVI is a kinase inhibitor indicated, in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Neurology
    Title:

    BRAFV600E-mutant glioblastoma responds to combination BRAF/MEK inhibition with encorafenib and binimetinib

    Published date:
    05/03/2022
    Excerpt:
    A 75-year-old man with vision loss and memory impairment was diagnosed….Targeted exon sequencing confirmed the diagnosis of BRAFV600E-mt glioblastoma with VAF of 36%....He was started on encorafenib/binimetinib resulting in decreased enhancement and clinical stability for 18 months, complicated only by renal insufficiency...encorafenib/binimetinib appear to confer favorable and lasting efficacy for BRAFV600E-mt glioma in both the parenchyma and leptomeninges.